Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Observational

Study Evaluating Multifaceted Support for the Implementation of Recommendations for the Prevention and Management of Anemia in Intensive Care Units

NCT07771192 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-09-01
Last updated
2026-08-18

Condition(s) studied

Anemia

Investigational drug(s) / intervention(s)

implementation of recommendations

implementation of recommendations: The study will be organized into three periods: * a pre-implementation phase, with no changes to usual care; * a period of implementation of the recommendations; * a post-implementation phase.

Study summary

STOP-A is a prospective, multicenter data study aimed at demonstrating the impact of multifaceted support for the implementation of recommendations on the prevention and management of anemia in intensive care, compared to previous practices, on hospital mortality in adult patients hospitalized in intensive care for ≥2 days. The timing of implementation in each center is determined randomly by stepped-wedge randomization.

As such, this is a pragmatic study that meets the international PRECIS-2 criteria.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Length of stay in intensive care is ≥ 2 days * The patient has at least one organ failure lasting 24 hours or more (catecholamine infusion and/or mechanical ventilation (invasive or NIV \> 6 hours/day)) * No objection to data collection (patient or relative) Exclusion Criteria: * Terminally ill patient with limited active treatment options within 72 hours of admission.

Primary outcome measure(s)

  • evaluate the impact of multifaceted support for STOP-A implementation on hospital mortality, taking into account the stepped wedge design structure. — Day 0 to Day 90
    in-hospital mortality, up to day 90

Trial sites (27)

FacilityCityRegionStatus
réanimation médicale CHU ANGERS Angers France
Ch Victor Dupouy Argenteuil France
CHRU BREST SITE HOPITAL CAVALE BLANCHE, réanimation chirurgicale Brest France
CHRU BREST SITE HOPITAL CAVALE BLANCHE, réanimation médicale Brest France
Ch Chartres Louis Pasteur-Le Coudray Chartres France
Ch de Cholet Cholet France
HOPITAL GABRIEL MONTPIED - CHU63, Réanimation Médico-Chrirugicale Clermont-Ferrand France
HOPITAL GABRIEL MONTPIED - CHU63, Réanimation Neurochirurgicale Clermont-Ferrand France
CHU Grenoble-HOPITAL SUD - CHU38 Grenoble France
CH de LAVAL Laval France
Centre Hospitalier Du Mans Le Mans France
Hopital St Eloi Chu Montpellier Montpellier France
Chru Nancy - Hopitaux de Brabois Nancy France
Hopital Laenec, CHU Nantes Nantes France
Hôtel Dieu, CHU Nantes Nantes France
Gcs Irm Beaujon Moleculaire Act, Ap-Hp Paris France
Hopital Cochin Tarnier Aphp Paris France
Hu Est Parisien Site St Antoine Aphp Paris France
Hu Paris Nord Site Bichat Aphp Paris France
HU PITIE SALPETRIERE APHP, Réanimation Chirurgicale Paris France
HU PITIE SALPETRIERE APHP, Réanimation Neuro-Chirurgicale Paris France
CHU LA MILETRIE, réanimation neurochirurgicale Poitiers France
Chru Rennes Site Pontchaillou Rennes France
Hopital de Hautepierre Strasbourg France
Hopital Haut-Leveque - Chu Talence France
Hopital Purpan Chu Toulouse Toulouse France
Chru Trousseau - Chambray Tours France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07771192 on ClinicalTrials.gov ↗ ← All trials in France